Clinical Trials | October 09, 2022
Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
Study achieves primary endpoint of radiographic progression-free survival
Study achieves primary endpoint of radiographic progression-free survival
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
One in two women with advanced ovarian cancer has an HRD-positive tumor
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
The funding round also saw participation from some of India's top angel investors and leading industry giants
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
Subscribe To Our Newsletter & Stay Updated
